Price T Rowe Associates Inc. MD Trims Stock Position in Replimune Group, Inc. (NASDAQ:REPL)

Price T Rowe Associates Inc. MD lessened its stake in shares of Replimune Group, Inc. (NASDAQ:REPL – Get Rating) by 29.1% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 4,171,171 shares of the company’s stock after selling 1,711,360 shares during the quarter. Price T Rowe Associates Inc. MD owned about 0.08% of Replimune Group worth $72,037,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of REPL. Metropolitan Life Insurance Co NY raised its position in Replimune Group by 41.1% in the 3rd quarter. Metropolitan Life Insurance Co NY now owns 2,452 shares of the company’s stock valued at $42,000 after purchasing an additional 714 shares during the last quarter. Point72 Hong Kong Ltd raised its position in Replimune Group by 449.3% in the 3rd quarter. Point72 Hong Kong Ltd now owns 3,252 shares of the company’s stock valued at $56,000 after purchasing an additional 2,660 shares during the last quarter. Amalgamated Bank raised its position in Replimune Group by 38.4% in the 3rd quarter. Amalgamated Bank now owns 5,246 shares of the company’s stock valued at $91,000 after purchasing an additional 1,456 shares during the last quarter. Quantbot Technologies LP raised its position in Replimune Group by 498.0% in the 2nd quarter. Quantbot Technologies LP now owns 5,980 shares of the company’s stock valued at $104,000 after purchasing an additional 4,980 shares during the last quarter. Finally, BNP Paribas Arbitrage SA raised its position in Replimune Group by 157.6% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 6,391 shares of the company’s stock valued at $112,000 after purchasing an additional 3,910 shares during the last quarter. Hedge funds and other institutional investors own 87.83% of the company’s stock.

Replimune Group Stock Performance

NASDAQ:REPL opened at $19.74 on Tuesday. The company has a quick ratio of 23.58, a current ratio of 23.58 and a debt-to-equity ratio of 0.09. Replimune Group, Inc. has a fifty-two week low of $13.05 and a fifty-two week high of $29.52. The stock has a market cap of $1.12 billion, a PE ratio of -6.90 and a beta of 1.69. The firm’s fifty day simple moving average is $25.16 and its 200-day simple moving average is $21.83.

Analyst Upgrades and Downgrades

REPL has been the subject of several research reports. SVB Leerink upped their price target on shares of Replimune Group from $30.00 to $34.00 and gave the company an “outperform” rating in a research report on Wednesday, December 7th. EF Hutton Acquisition Co. I began coverage on shares of Replimune Group in a research report on Thursday, January 5th. They set a “buy” rating and a $60.00 price objective for the company. HC Wainwright upped their price objective on shares of Replimune Group from $48.00 to $50.00 and gave the stock a “buy” rating in a research report on Friday, February 10th. BMO Capital Markets upped their price objective on shares of Replimune Group from $40.00 to $70.00 and gave the stock an “outperform” rating in a research report on Monday, December 12th. Finally, Piper Sandler upped their price objective on shares of Replimune Group from $43.00 to $58.00 in a research report on Wednesday, December 14th. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Replimune Group presently has an average rating of “Buy” and an average price target of $51.86.

About Replimune Group

(Get Rating)

Replimune Group, Inc is a clinical-stage biotechnology company, which engages in the development of oncolytic immunotherapy product candidates through immulytic platform. Its product candidates include RP1, RP2, and RP3. The firm’s Oncolytic immunotherapy is a cancer treatment that exploits the ability of certain viruses to selectively replicate in and directly kill tumors, as well as induce a potent, patient-specific, anti-tumor immune response.